传「喜茶」、「奈雪的茶」寻求明年在港上市 分别筹4-5亿元
据内地传媒报道,内地连锁公司饮品公司「喜茶」与「奈雪的茶」寻求於2021年在香港上市,分别筹资4-5亿元。
报道指喜茶于2016年8月及2018年4月分别获1亿及4亿元人民币(下同)的融资,近期有传公司将完成新一轮融资,由高瓴资本及蔻图资本联合领投,料估值将达160亿元。
而奈雪的茶于2015年成立,公司经过四轮融资,对上一轮2018年3月的融资其估值已达60亿元,传公司亦即将完成新一轮近亿美元的融资,领投方为深创投。据消息人士指奈雪的茶考虑到早前瑞幸咖啡造假引发的中概股风波,已将上市地由美国转向香港。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.